179 related articles for article (PubMed ID: 35359368)
1. Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review.
Lin Y; Zhu W; Wu B; Lan H
Front Oncol; 2022; 12():824308. PubMed ID: 35359368
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Sarcoid-like reaction in cases treated by checkpoint inhibitors.
Paydas S
Med Oncol; 2021 Feb; 38(3):29. PubMed ID: 33598792
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: case report and review of the literature.
Keane F; Yogiaveetil E; Kezlarian B; Lagratta M; Segal NH; Abou-Alfa G; O'Reilly EM; Saltz L; El Dika I
J Gastrointest Oncol; 2024 Feb; 15(1):500-507. PubMed ID: 38482249
[TBL] [Abstract][Full Text] [Related]
5. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
6. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
[TBL] [Abstract][Full Text] [Related]
7. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
8. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.
Apalla Z; Kemanetzi C; Papageorgiou C; Bobos M; Manoli M; Fotiadou C; Hatzibougias D; Boukovinas I; Stergiou E; Levva S; Lallas A; Lazaridou E
Dermatol Ther; 2021 Jan; 34(1):e14618. PubMed ID: 33263945
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab induced sarcoid-like pulmonary lymphadenopathy.
Sanderson E; Wimaleswaran H; Senko C; White S; McDonald CF
Respirol Case Rep; 2020 Apr; 8(3):e00542. PubMed ID: 32110415
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.
Mazumder A; Mehrmal S; Chaudhry S
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37463781
[TBL] [Abstract][Full Text] [Related]
13. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence.
Hiraki T; Hatanaka M; Arimura A; Kawahira H; Kirishima M; Kitazono I; Horinouchi M; Higashi M; Kanekura T; Tanimoto A
J Cutan Pathol; 2020 Feb; 47(2):154-160. PubMed ID: 31437317
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
16. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
20. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]